Skip to main content

Table 1 Baseline clinical characteristics according to HBcAb status in HBsAg-negative DLBCL patients

From: Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival

Characteristic

HBcAb-negative [cases (%)]

HBcAb-positive [cases (%)]

P value

Total

110

55

 

Sex

  

0.434

 Male

67 (60.9)

30 (54.5)

 Female

43 (39.1)

25 (45.5)

ECOG PS

  

0.525

 0–1

96 (87.3)

46 (83.6)

 ≥2

14 (12.7)

9 (16.4)

Bulky mass

  

0.619

 Yes

28 (25.5)

16 (29.1)

 No

82 (74.5)

39 (70.9)

B symptoms

  

0.448

 −

80 (72.7)

43 (78.2)

 +

30 (27.3)

12 (21.8)

Ann Arbor stage

  

0.698

 I–II

52 (47.3)

28 (50.9)

 III-IV

57 (51.8)

27 (49.1)

Liver involvement

  

0.720

 −

104 (94.5)

53 (96.4)

 +

6 (5.5)

2 (3.6)

IPI score

  

0.851

 0–1

48 (43.6)

21 (38.2)

 2

28 (25.4)

17 (30.9)

 3

23 (20.9)

11 (20.0)

 4-5

10 (9.1)

6 (10.9)

ALT

  

0.874

 ≤40 U/L

95 (86.4)

47 (85.5)

 >40 U/L

15 (13.6)

8 (14.5)

AST

  

0.863

 ≤45 U/L

97 (88.2)

49 (89.1)

 >45 U/L

13 (11.8)

6 (10.9)

TB

  

0.852

 ≤20.5 μmol/L

99 (90.0)

50 (90.9)

 >20.5 μmol/L

11 (10.0)

5 (9.1)

LDH

  

0.910

 ≤245 U/mL

67 (60.9)

33 (60.0)

 >245 U/mL

43 (39.1)

22 (40.0)

HBsAb

  

<0.001

 –

82 (74.5)

3 (5.5)

 +

28 (25.5)

52 (94.5)

HBeAb

  

0.251

 –

102 (92.7)

48 (87.3)

 +

8 (7.3)

7 (12.7)

  1. HBcAb, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, international prognostic index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TB, total bilirubin; LDH, lactate dehydrogenase; HBsAb, hepatitis B surface antibody; HBeAb, hepatitis B e antibody. The information of Ann Arbor stage and IPI were available for 164 patients.